Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China

Table 4 Nine potential risk factors were considered the association with incidence of HIV-1 DRMs among participants experiencing treatment failure

Variable	Mutation identified (n = 914)	No mutations identified (n = 1381)	OR	P	95%CI
Gender
Male	654	994	0.95	0.68	0.76–1.20
Female	260	387	1
Age
< 14	20	12	1
15~29	146	224	0.22	0.32	0.11–4.37
30~44	314	461	0.21	0.31	0.01–4.22
45~59	255	374	0.18	0.26	0.01–3.61
≥ 60	179	310	0.20	0.30	0.01–4.06
Regimen
AZT + 3TC + NVP/EFV	468	424	1
D4T + 3TC + NVP/EFV	102	62	1.39	0.10	0.94–2.05
TDF + 3TC + NVP/EFV	287	396	0.40	0.00	0.32–0.51
Second line regimens	57	499	0.08	0.00	0.06–0.11
Subtype
AE	607	866	1
BC	126	285	0.62	0.00	0.48–0.81
B	103	160	0.80	0.16	0.59–1.09
C	36	45	1.18	0.55	0.69–2.00
Other	42	25	1.36	0.28	0.77–2.39
CD4 abs count (cells/mm³)
≤ 200	685	705	3.16	0.00	2.55–3.91
> 200	229	676	1	1.00
WHO Stage
I	449	695	1
II	237	358	0.9	0.41	0.70–1.16
III	129	214	0.81	0.20	0.59–1.12
IV	99	114	1.08	0.68	0.74–1.59
Route of transmission
BLOOD transmission	12	18	1
PWID	79	148	1.02	0.96	0.42–2.50
MSM	90	128	1.44	0.43	0.58–3.58
Heterosexual	676	1024	1.27	0.58	0.55–2.95
Vertical transmission	21	13	0.49	0.64	0.02–9.80
Unknown	36	50	1.32	0.58	0.50–3.49
Recently 7 days number of doses missed
0	369	866	1
≥ 1	545	515	2.94	0.00	2.38–3.63
Symptoms in recent three months
No			1
Yes			1.48	0.00	1.18–1.85

ISSN: 1743-422X